 |
|
| Type | Public (LSE: SHP) (NASDAQ: SHPGY) (TSX:SHPGY-Q) |
|---|---|
| Founded | 1986 |
| Headquarters | Basingstoke, England, UK |
| Key people | Matthew Emmens, Chairman Angus Russell, CEO |
| Industry | Pharmaceuticals |
| Revenue | $3,022.2 million (2008) |
| Operating income | $412.0 million (2008) |
| Net income | $156.0 million (2008) |
| Website | www.shire.com |
Shire plc (LSE: SHP), (NASDAQ: SHPGY), (TSX:SHPGY-Q) is a British manufacturer of pharmaceuticals including Adderall XR, Carbatrol, Fosrenol, and the recently released Vyvanse.
Contents |
History
Shire was founded by Harry Stratford following discussions with Dr James Murray in 1986.[1] It was first listed on the London Stock Exchange in 1996[1] and in 1997 it went on to acquire Pharmavene and Richmond Pharmaceutical Company.[1] In 2007 it acquired New River Pharmaceuticals Inc, a leading US drug maker, for $2.3bn.[2]
Operations
The Company seeks to develop and market products within advanced biotechnology for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
The Company focuses its drug research and development on the relatively common mental abnormality Attention Deficit Hyperactivity Disorder (ADHD), as is made evident by the fact that three of its currently leading medications (Adderall/Adderall XR, Daytrana, and the newly developed Vyvanse), are intended for that disorder. However the Company also works on gastrointestinal (GI) treatments, human genetic therapies (HGT) and renal diseases.
Products
| Name | Annual revenue[3] | Indication |
|---|---|---|
| Adderall XR | $1.1B | Attention Deficit Hyperactivity Disorder (ADHD) |
| Vyvanse | $318.9M | Attention Deficit Hyperactivity Disorder (ADHD) |
| Elaprase | $305.1M | Hunter syndrome (lysosomal storage disorder) |
| Pentasa | $185.5M | Gastrointestinal (Ulcerative colitis) |
| Replagal | $176.1M | Fabry disease (lysosomal storage disorder) |
| Fosrenol | $155.4M | Renal disease |
| Lialda/Mezavant | $140.4M | Gastrointestinal (Ulcerative colitis) |
| Daytrana | $78.7M | Attention Deficit Hyperactivity Disorder (ADHD) |
| Xagrid (sold as Agrylin in the U.S.) | $78.7M | Essential thrombocytosis |
| Carbatrol | $75.9M | Epilepsy |
| Calcichew (UK) | $52.8M | Calcium supplements |
| Reminyl/Reminyl XL | $34.4M | Alzheimer's disease |
| Firazyr | $0.5M | Cardiovascular (Hereditary angioedema) |
Royalty income
| Name | Annual revenue[4] | Indication | Licensee |
|---|---|---|---|
| 3TC (Lamivudine) | $140.2M | HIV | GlaxoSmithKline |
| Zeffix (Lamivudine) | $40.3M | Chronic hepatitis B | GlaxoSmithKline |
Locations
The corporate offices are located in Basingstoke, Hampshire, UK. Other major offices are located in the United States in Wayne, Pennsylvania and Cambridge, Massachusetts. In addition, Shire owns a manufacturing site in Owings Mills, Maryland. The company has recently announced that it will move its tax domicile to Ireland.[5] The move will be effected through the creation of a new holding company in Jersey, which will pay reduced tax on global earnings in Ireland. The new structure is thought to be motivated mainly by the rule that royalties on patents lodged in Ireland are tax free.
Corporate leadership
The non-executive Board Chairman is Matthew Emmens. Angus Russell is the Chief Executive Officer. The President of the Human Genetic Therapies division is Sylvie Gregoire and Michael Cola is the President of Specialty Pharmaceuticals.
References
External links
|
||||||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
